share_log

ATE.TO: Plans on Track for Acute Pain Program for Otenaproxesul...

Benzinga Real-time News ·  Sep 12, 2022 12:05

By David Bautz, PhD

OTC:ATBPF | TSX:ATE.TO

READ THE FULL ATE.TO RESEARCH REPORT

Business Update

Phase 2 Post-Operative Pain Program to Initiate in Calendar 4Q22

Antibe Therapeutics, Inc. (OTC:ATBPF) (TSX:ATE) is developing otenaproxesul as a solution to the dose-related gastrointestinal (GI) side effects associated with non-steroidal anti-inflammatory drugs (NSAIDs). It uses naproxen as a base molecule with a hydrogen sulfide moiety covalently attached. Hydrogen sulfide (H2S) is an important gasotransmitter, which is a gas that serves as an important signaling molecule in the body.

The company is developing otenaproxesul for the management...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment